Public disclosures

AEON insider disclosures

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
Wilson Alexander Blair

CLO, CSO and Corp Secretary · AEON Biopharma, Inc.

AEON

AEON Biopharma, Inc.

Buy
Filing details

SEC transaction code P

Class A Common Stock · Direct ownership · Reported balance after transaction: 2318711 · SEC code covers open-market or private transactions · The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1235 to $0.1300 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2026-11-202026-11-20

≈ $17,478.93

135,706 shares/units

SEC 4Follow
Sy Jennifer

Chief Accounting Officer · AEON Biopharma, Inc.

AEON

AEON Biopharma, Inc.

Buy
Filing details

SEC transaction code P

Class A Common Stock · Direct ownership · Reported balance after transaction: 1655022 · SEC code covers open-market or private transactions · The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1290 to $0.1300 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2026-11-192026-11-20

≈ $19,984.60

153,846 shares/units

SEC 4Follow
Bancroft Robert E.

President and CEO · Director · AEON Biopharma, Inc.

AEON

AEON Biopharma, Inc.

Buy
Filing details

SEC transaction code P

Class A Common Stock · Direct ownership · Reported balance after transaction: 3329436 · SEC code covers open-market or private transactions · The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1213 to $0.1345 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2026-11-192026-11-20

≈ $19,590.02

152,333 shares/units

SEC 4Follow
Daewoong Co., Ltd

10% owner · AEON Biopharma, Inc.

AEON

AEON Biopharma, Inc.

Exercise or conversion
Filing details

SEC transaction code X

Pre-Funded Warrant (right to buy) · Derivative security · Indirect ownership · By Daewoong Pharmaceutical Co., Ltd. · Reported balance after transaction: 0 · On October 30, 2026 (the "Exercise Date"), DWP exercised in full, on a cashless basis pursuant to Section 10 of the Pre-Funded Warrant, Pre-Funded Warrants to purchase 11,236,631 shares of Class A Common Stock at an exercise price of $0.0001 per share. No cash was paid by DWP in connection with the exercise. · The Pre-Funded Warrants were exercisable at any time on or after January 21, 2026 and did not expire until exercised in full. Following the exercise described in footnotes (2) and (3), no Pre-Funded Warrants remain outstanding. · Daewoong Co., Ltd. ("DWC") owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. ("DWP"), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. · None.

2026-10-302026-11-10

11,236,631 shares/units

SEC 4Follow
Daewoong Co., Ltd

10% owner · AEON Biopharma, Inc.

AEON

AEON Biopharma, Inc.

Other transaction
Filing details

SEC transaction code J

Class A Common Stock, $0.0001 par value per share · Indirect ownership · By Daewoong Pharmaceutical Co., Ltd. · Reported balance after transaction: 23184523 · Represents 3,822 shares of Class A Common Stock withheld by the Issuer in satisfaction of the aggregate exercise price of the Pre-Funded Warrants in accordance with the net exercise formula set forth in the Pre-Funded Warrant, based on the closing sale price of $0.294 per share on October 29, 2026, the trading day immediately preceding the Exercise Date. As a result of the cashless exercise, 11,232,809 shares of Class A Common Stock were issued to DWP. · Daewoong Co., Ltd. ("DWC") owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. ("DWP"), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. · None.

2026-10-302026-11-10

3,822 shares/units

SEC 4Follow
Daewoong Co., Ltd

10% owner · AEON Biopharma, Inc.

AEON

AEON Biopharma, Inc.

Exercise or conversion
Filing details

SEC transaction code X

Class A Common Stock, $0.0001 par value per share · Indirect ownership · By Daewoong Pharmaceutical Co., Ltd. · Reported balance after transaction: 23188345 · On October 30, 2026 (the "Exercise Date"), DWP exercised in full, on a cashless basis pursuant to Section 10 of the Pre-Funded Warrant, Pre-Funded Warrants to purchase 11,236,631 shares of Class A Common Stock at an exercise price of $0.0001 per share. No cash was paid by DWP in connection with the exercise. · Daewoong Co., Ltd. ("DWC") owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. ("DWP"), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. · None.

2026-10-302026-11-10

11,236,631 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement